Castañon, M.M.; Lauricella, A.M.; Kordich, L.; Quintana, I. "Plasma homocysteine cutoff values for venous thrombosis" (2007) Clinical Chemistry and Laboratory Medicine. 45(2):232-236
Estamos trabajando para incorporar este artículo al repositorio
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor


Background: Hyperhomocysteinemia is considered an independent risk factor for vascular occlusive diseases. To date, there is no general agreement on hyperhomocysteinemia cutoff values. Methods: To establish a homocysteine cutoff value, we performed a case-control study in 118 patients suffering from venous thrombosis and in 115 healthy subjects. We calculated odds ratios at different cutoff points and considered hyperhomocysteinemia as homocysteine levels above which the risk of venous thrombosis was increased. Results: Initially we used the 97.5th percentiles for fasting homocysteine levels in the control group to calculate odds ratios (95% CI) of 9.5 (2.6-35.3), 3.7 (0.8-17.9) and 4.5 (1.7-123.8) for the total population, women and men, respectively. When individuals with well-known thrombotic risk factors were excluded (selected population), odds ratios were 10.5 (2.7- 41.1), 6.5 (1.3-32.1) and 11.2 (1.2-103.1), respectively, confirming hyperhomocysteinemia as an independent risk factor for venous thrombosis. We did not find any association of venous thrombosis with the homozygous methylenetetrahydrofolate reductase C677T mutation. When the hyperhomocysteinemia cutoff was set at other arbitrary points, odds ratios for the selected population were statistically significant only at >12 μmol/L. Conclusions: Based on our results, we propose 12 μmol/L as the hyperhomocysteinemia cutoff value. © 2007 by Walter de Gruyter.


Documento: Artículo
Título:Plasma homocysteine cutoff values for venous thrombosis
Autor:Castañon, M.M.; Lauricella, A.M.; Kordich, L.; Quintana, I.
Filiación:Laboratorio de Hemostasia Y Trombosis, Departamento de Química Biológica, Universidad de Buenos Aires, Buenos Aires, Argentina
Departamento de Química Biológica, Facultad de Ciencias Exactas Y Naturales, Ciudad Universitaria, (C1428EHA) Buenos Aires, Argentina
Palabras clave:Cutoff values; Hyperhomocysteinemia; Venous thrombosis; 5,10 methylenetetrahydrofolate reductase (FADH2); homocysteine; adult; article; controlled study; disease association; female; human; hyperhomocysteinemia; major clinical study; male; priority journal; risk factor; statistical significance; vein thrombosis; Adult; Case-Control Studies; Female; Homocysteine; Humans; Hyperhomocysteinemia; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Odds Ratio; Venous Thrombosis
Página de inicio:232
Página de fin:236
Título revista:Clinical Chemistry and Laboratory Medicine
Título revista abreviado:Clin. Chem. Lab. Med.
CAS:5,10 methylenetetrahydrofolate reductase (FADH2), 9028-69-7; homocysteine, 454-28-4, 6027-13-0; Homocysteine, 454-28-4; Methylenetetrahydrofolate Reductase (NADPH2),


  • Rosendaal, F.R., Venous thrombosis: A multicausal disease (1999) Lancet, 353, pp. 1167-1173
  • Guba, S.C., Fonseca, V., Fink, L.M., Hyperhomocysteinemia and thrombosis (1999) Semin Thromb Hemost, 25, pp. 291-309
  • Ueland, M., Homocysteine species as components of plasma redox thiol status (1995) Clin Chem, 41, pp. 340-342
  • Rozen, R., Genetic modulation of homocysteinemia (2000) Semin Thromb Hemost, 26, pp. 255-261
  • Frosst, P., Blom, H.J., Milos, R., Goyette, P., Sheppard, C.A., Matthews, R.G., A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase (1995) Nat Genet, 10, pp. 111-113
  • Schneede, J., Refsum, H., Ueland, P.M., Biological and environmental determinants of plasma homocysteine (2000) Semin Thromb Hemost, 26, pp. 263-279
  • Lahiri, D.K., Nurnberger, J.I., A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies (1991) Nucleic Acids Res, 19, p. 5444
  • Bertina, R.M., Koeleman, B.P., Koster, T., Rosendaal, F.R., Dirven, R.J., de Ronde, H., Mutation in blood coagulation factor V associated with resistance to activated protein C (1994) Nature, 369, pp. 64-67
  • Poort, S.R., Rosendaal, F.R., Reitsma, P.H., Berina, R.M., A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis (1996) Blood, 88, pp. 3698-3703
  • McCully, K.S., Vascular pathology of homocysteinaemia: Implications for the pathogenesis of arteriosclerosis.Am (1969) J Pathol, 56, pp. 111-128
  • Graham, I.M., Daly, L.E., Refsum, H.M., Robinson, K., Brattstrom, L.E., Ueland, P.M., Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project (1997) J Am Med Assoc, 277, pp. 1775-1781
  • Herrmann, W., The importance of hyperhomocysteinemia as a risk factor for diseases: An overview (2001) Clin Chem Lab Med, 39, pp. 666-674
  • Refsum, H., Nurk, E., Smith, A.D., Ueland, P.M., Gjesdal, C.G., Bjelland, I., The Hordaland Homocysteine study: A community-based study of homocysteine, its determinants, and associations with disease (2006) J Nutr, 136, pp. 1731-1740
  • Ueland, P.M., Refsum, H., Stabler, S., Malinow, M.R., Andersson, A., Allen, R.H., Total homocysteine in plasma or serum: Methods and clinical applications (1993) Clin Chem, 39, pp. 1764-1779
  • Selhub, J., Jacques, P.F., Rosenberg, I.H., Rogers, G., Bowman, B.A., Gunter, E.W., Serum total homocysteine concentrations in the Third National Health and Nutrition Examination Survey (1991-1994): Population reference ranges and contribution of vitamin status to high serum concentration (1999) Ann Intern Med, 131, pp. 331-339
  • Rasmussen, K., Moller, J., Lyngbak, M., Pedersen, A., Dybkjaer, L., Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation (1996) Clin Chem, 42, pp. 630-636
  • Ubbink, J., Becker, P., Hayward Vermaak, W.J., Delport, R., Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine (1995) Clin Chem, 41, pp. 1033-1037
  • Fokkema, M.R., Weijer, J.M., Dijck-Brouwer, D.A., van Doormaal, J.J., Muskiet, F.A., Influence of vitamin-optimized plasma homocysteine cutoff values on the prevalence of hyperhomocysteinemia in healthy adults (2001) Clin Chem, 47, pp. 1001-1007
  • Refsum, H., Smith, A.D., Ueland, P.M., Nexo, E., Clarke, R., McPartlin, J., Facts and recommendations about total homocysteine determinations: An expert opinion (2004) Clin Chem, 50, pp. 3-32
  • Den Heijer, M., Lewington, S., Clarke, R., Homocysteine, MTHFR and risk of venous thrombosis: A meta-analysis of published epidemiological studies (2005) J Thromb Haemost, 3, pp. 292-299
  • Oger, E., Lacut, K., Le Gal, G., Couturaud, F., Guenet, D., Abalain, J.H., Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: Results from the EDITH study: a hospitalbased case-control study (2006) J Thromb Haemost, 4, pp. 793-799
  • Quere, I., Gris, J.C., Dauzat, M., Homocysteine and venous thrombosis (2005) Semin Vasc Med, 5, pp. 183-189
  • Obeid, R., Hakki, T., Jouma, M., Herrmann, W., The risk of venous thromboembolism associated with the factor V Leiden mutation and low B-vitamin status (2003) Clin Chem Lab Med, 41, pp. 1357-1362
  • Keijzer, M.B., den Heijer, M., Blom, H.J., Bos, G.M., Willems, H.P., Gerrits, W.B., Interaction between hyperhomocysteinemia, mutated methylene-tetrahydrofolate reductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis (2002) Thromb Haemost, 88, pp. 723-728
  • den Heijer, M., Koster, T., Henk, J., Blom, H.J., Bos, G.M., Briët, E., Hyperhomocysteinemia as a risk factor for deepvein thrombosis (1996) N Engl J Med, 334, pp. 759-762
  • Arruda, V.R., von Zuben, P.M., Chiaparini, L.C., Annichino-Bizzacchi, J.M., Costa, F.F., The mutation Ala677 → Val in the methylene tetrahydrofolate reductase gene: A risk factor for arterial disease and venous thrombosis (1997) Thromb Haemost, 77, pp. 818-821
  • Margaglione, M., D'Andrea, G., d'Addedda, M., Giuliani, N., Cappucci, G., Iannaccone, L., The methylene-tetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A 20210 mutation (1998) Thromb Haemost, 79, pp. 907-911
  • Ray, J.G., Shmorgun, D., Chan, W.S., Common C677T polymorphism of the methylene-tetrahydrofolate reductase gene and the risk of venous thromboembolism: Metaanalysis of 31 studies (2002) Pathophysiol Haemost Thromb, 32, pp. 51-58
  • Tsai, A.W., Cushman, M., Tsai, M.Y., Heckbert, S.R., Rosamond, W.D., Aleksic, N., Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE) (2003) Am J Hematol, 72, pp. 192-200


---------- APA ----------
Castañon, M.M., Lauricella, A.M., Kordich, L. & Quintana, I. (2007) . Plasma homocysteine cutoff values for venous thrombosis. Clinical Chemistry and Laboratory Medicine, 45(2), 232-236.
---------- CHICAGO ----------
Castañon, M.M., Lauricella, A.M., Kordich, L., Quintana, I. "Plasma homocysteine cutoff values for venous thrombosis" . Clinical Chemistry and Laboratory Medicine 45, no. 2 (2007) : 232-236.
---------- MLA ----------
Castañon, M.M., Lauricella, A.M., Kordich, L., Quintana, I. "Plasma homocysteine cutoff values for venous thrombosis" . Clinical Chemistry and Laboratory Medicine, vol. 45, no. 2, 2007, pp. 232-236.
---------- VANCOUVER ----------
Castañon, M.M., Lauricella, A.M., Kordich, L., Quintana, I. Plasma homocysteine cutoff values for venous thrombosis. Clin. Chem. Lab. Med. 2007;45(2):232-236.